These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The neurotoxicity of misonidazole: potential modifying role of phenytoin sodium and dexamethasone. Wasserman TH; Phillips TL; Van Raalte G; Urtasun R; Partington J; Koziol D; Schwade JG; Gangji D; Strong JM Br J Radiol; 1980 Feb; 53(626):172-3. PubMed ID: 6245744 [No Abstract] [Full Text] [Related]
4. Plasma concentration of misonidazole and peripheral neuropathy. Marten TR Am J Clin Oncol; 1982 Apr; 5(2):239-40. PubMed ID: 6283876 [No Abstract] [Full Text] [Related]
5. Neurotoxicity of Adriamycin and misonidazole in the mouse. Boegman RJ; Scarth B; Dragovic L; Robertson DM Exp Neurol; 1985 Jan; 87(1):1-8. PubMed ID: 2981696 [TBL] [Abstract][Full Text] [Related]
6. Dose-response curves for predicting misonidazole-induced peripheral neuropathy. Schwade JG; Makuch RW; Strong JM; Glatstein E Cancer Treat Rep; 1982 Sep; 66(9):1743-50. PubMed ID: 6288238 [TBL] [Abstract][Full Text] [Related]
7. Misonidazole peripheral neuropathy: its relationship to plasma concentration and other drugs. Walker MD; Strike TA Cancer Clin Trials; 1980; 3(2):105-9. PubMed ID: 6253094 [TBL] [Abstract][Full Text] [Related]
9. The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum. Saunders ME; Dische S; Anderson P; Flockhart IR Br J Cancer Suppl; 1978 Jun; 3():268-70. PubMed ID: 209808 [TBL] [Abstract][Full Text] [Related]
10. The neurotoxicity of misonidazole: potential modifying role of dexamethasone. Workman P Br J Radiol; 1980 Jul; 53(631):736. PubMed ID: 7426903 [No Abstract] [Full Text] [Related]
11. Oncogenic transformations in vitro produced by misonidazole. Miller RC; Hall EJ Cancer Clin Trials; 1980; 3(1):85-90. PubMed ID: 7389040 [TBL] [Abstract][Full Text] [Related]
12. The optimum regime for the administration of misonidazole and the establishment of multi-centre clinical trials. Dische S; Saunders MI; Flockhart IR Br J Cancer Suppl; 1978 Jun; 3():318-21. PubMed ID: 209811 [TBL] [Abstract][Full Text] [Related]
13. Fatal misonidazole-induced encephalopathy: an RTOG case report. Kun LE; Ho KC; Moulder JE Cancer; 1982 Feb; 49(3):423-6. PubMed ID: 7059905 [TBL] [Abstract][Full Text] [Related]
14. The role of microsomal enzyme inducers in the reduction of misonidazole neurotoxicity. Jones DH; Bleehen NM; Workman P; Smith NC Br J Radiol; 1983 Nov; 56(671):865-70. PubMed ID: 6626878 [TBL] [Abstract][Full Text] [Related]
15. "Battered data"--some clinical effects of the abuse of multiple regression methods: a second look at some observations on Ro07-0582 (Misonidazole). Herbert DE Med Phys; 1981; 8(6):848-64. PubMed ID: 6275254 [TBL] [Abstract][Full Text] [Related]
16. An investigation in vitro of the chromosomal effects of misonidazole. Schwartz LE; Gerd CR; Miller RC Int J Radiat Oncol Biol Phys; 1980 Jul; 6(7):915-21. PubMed ID: 7204132 [No Abstract] [Full Text] [Related]
17. Misonidazole-a drug for trial in radiotherapy and oncology. Dische S; Saunders MI; Flockhart IR; Lee ME; Anderson P Int J Radiat Oncol Biol Phys; 1979 Jun; 5(6):851-60. PubMed ID: 227822 [No Abstract] [Full Text] [Related]
18. Clinical experience with misonidazole: high dose fractions versus daily low doses. Kogelnik HD Cancer Clin Trials; 1980; 3(2):179-86. PubMed ID: 6253098 [TBL] [Abstract][Full Text] [Related]
19. New side effect of the hypoxic cell sensitizer, misonidazole. Partington J; Koziol D; Chapman D; Rabin H; Urtasun RC Cancer Treat Rep; 1979 Jan; 63(1):123-5. PubMed ID: 217536 [TBL] [Abstract][Full Text] [Related]
20. Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizer. Wasserman TH; Phillips TL; Johnson RJ; Gomer CJ; Lawrence GA; Sadee W; Marques RA; Levin VA; VanRaalte G Int J Radiat Oncol Biol Phys; 1979 Jun; 5(6):775-86. PubMed ID: 227821 [No Abstract] [Full Text] [Related] [Next] [New Search]